Michael Dummeldinger

Title: Michael Dummeldinger: Innovator in Pharmaceutical Chemistry

Introduction

Michael Dummeldinger is a notable inventor based in Plainsboro, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as LPA antagonists. With a total of 3 patents, his work is recognized for its potential impact on treating various medical conditions.

Latest Patents

Dummeldinger's latest patents include a process for preparing carbamoyloxymethyl triazole cyclohexyl acid compounds. This invention describes improved methods and intermediates for synthesizing these compounds, which are useful as LPA antagonists. Another significant patent involves the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide. This compound is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases, such as psoriasis.

Career Highlights

Michael Dummeldinger is associated with Bristol-Myers Squibb Company, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing therapeutic options for patients suffering from complex diseases.

Collaborations

Dummeldinger collaborates with esteemed colleagues, including Michael J. Smith and Ke Chen, to further enhance the research and development of new pharmaceutical compounds.

Conclusion

Michael Dummeldinger's contributions to pharmaceutical chemistry exemplify the importance of innovation in medicine. His patents and ongoing research hold promise for improving treatment options for patients with auto-immune and auto-inflammatory diseases.